Vertex Pharmaceuticals price target raised to $450 from $433 at Scotiabank

Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

TipRanks

Wed, Feb 12, 2025, 7:41 AM 1 min read

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating consensus for Q4 and FY24, the analyst tells investors. The firm is raising its price target on the stock to reflect updated sales expectations in cystic fibrosis.

Maximize Your Portfolio with Data Driven Insights:

Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on VRTX: